Local Antineoplastic Particle Delivery with Systemic Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments often struggle to effectively target tumors while minimizing systemic toxicity and enhancing immune response.
Innovation Solution
The method involves the local administration of antineoplastic agent particles, such as taxane particles, directly to tumors, combined with systemic administration of an immunotherapeutic agent, to stimulate both local and systemic immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional systemic chemotherapy is used to treat cancer, then tumor cells can be targeted throughout the body, but systemic toxicity increases and immune response is not effectively enhanced
Solution Approach 1:
The treatment is divided into two distinct components: local delivery of antineoplastic particles directly to the tumor site and systemic delivery of immunotherapeutic agents. This segmentation allows each component to perform its specialized function - the particles provide localized cytotoxic effect while the immunotherapeutic agent stimulates systemic immune response, thereby reducing overall systemic toxicity compared to traditional chemotherapy.
Solution Approach 2:
The patent applies local quality by delivering antineoplastic particles directly to the tumor through various local administration routes (topical, intratumoral, intraperitoneal, pulmonary). This creates a high concentration of drug at the tumor site while maintaining low systemic levels, thereby achieving effective tumor treatment with reduced systemic toxicity.
2Reliability
If traditional chemotherapy is used to treat cancer, then tumor cells can be targeted, but immune response enhancement is limited
Solution Approach 1:
The patent merges two different therapeutic approaches: local delivery of antineoplastic particles and systemic delivery of immunotherapeutic agents. This combination creates a synergistic effect where the particles kill tumor cells locally and release tumor antigens, which then stimulate the immunotherapeutic agent to activate a systemic immune response, thereby enhancing overall cancer treatment efficacy beyond what either therapy could achieve alone.
Solution Approach 2:
The immunotherapeutic agent acts as an intermediary that bridges the local tumor destruction caused by antineoplastic particles and the systemic immune response. The particles destroy tumor cells and release antigens, which the immunotherapeutic agent then utilizes to activate and direct the immune system against cancer cells throughout the body.
3Object-affected harmful factors
If local administration of antineoplastic particles is used, then systemic toxicity is reduced, but comprehensive tumor coverage is limited
Solution Approach 1:
The treatment strategy segments the cancer fight into local and systemic components. Local administration of antineoplastic particles handles the primary tumor burden with minimal systemic exposure, while systemic administration of immunotherapeutic agents provides comprehensive coverage against metastatic disease and residual tumor cells throughout the body, thereby achieving both reduced toxicity and comprehensive coverage.
Data Source
AI summary
Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.